1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Title

Showing 1,267 results.

Thumbnail for Real-World Treatment Patterns, Chimeric Antigen Receptor (CAR) T Cell Therapy Referral Barriers, and Time-to-Next Treatment (TTNT) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) Who Experienced Progression ≤24 Months of First-Line Che

CT - 341

Real-World Treatment Patterns, Chimeric Antigen Receptor (CAR) T Cell Therapy Referral Barriers, and Time-to-Next Treatment (TTNT) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) Who Experienced Progression ≤24 Months of First-Line Che

Sairah Ahmed

Poster Presenter: Sairah Ahmed

HL - 1598

Real-World Uptake of Frontline Brentuximab Vedotin in Classical Hodgkin Lymphoma: A National Cancer Database Analysis

Rita Ahmad

Poster Presenter: Rita Ahmad

Thumbnail for Real-World Use of Pacritinib in Myelofibrosis: Results From the TriNetX Analysis on Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Platelets =50Χ109/L at Initiation (TRIPAC)

MPN - 1200

Real-World Use of Pacritinib in Myelofibrosis: Results From the TriNetX Analysis on Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Platelets =50Χ109/L at Initiation (TRIPAC)

Faizan Sattar

Poster Presenter: Faizan Sattar

Thumbnail for Real-World Utilization and Survival Outcomes of Palliative Radiation Therapy in Patients With Multiple Myeloma Receiving BCMA-Targeted Therapies: A Propensity Score-Matched TriNetX Analysis

MM - 948

Real-World Utilization and Survival Outcomes of Palliative Radiation Therapy in Patients With Multiple Myeloma Receiving BCMA-Targeted Therapies: A Propensity Score-Matched TriNetX Analysis

Wei Ju Lin

Poster Presenter: Wei Ju Lin

Thumbnail for Redefining "Safe" Anthracycline Limits: A Restricted Cubic Spline Meta-Analysis of Continuous Cumulative Dosing and Non-Linear Cardiotoxicity in Hodgkin Lymphoma Survivors

HL - 1461

Redefining "Safe" Anthracycline Limits: A Restricted Cubic Spline Meta-Analysis of Continuous Cumulative Dosing and Non-Linear Cardiotoxicity in Hodgkin Lymphoma Survivors

Haroon Alamy

Poster Presenter: Haroon Alamy

Thumbnail for Redefining the Horizon: A Deep Survival Mixture Meta-Analysis Quantifying the Statistical Cure Fraction of Cellular Therapies in Relapsed Multiple Myeloma

MM - 1520

Redefining the Horizon: A Deep Survival Mixture Meta-Analysis Quantifying the Statistical Cure Fraction of Cellular Therapies in Relapsed Multiple Myeloma

Haroon Alamy

Poster Presenter: Haroon Alamy

Thumbnail for Reduced Mortality, Cytopenias, and Cardiovascular Events With Asciminib ComparedWith Ponatinib in Previously Treated Chronic Myeloid Leukemia: A Propensity-MatchedReal-World Analysis

CML - 1365

Reduced Mortality, Cytopenias, and Cardiovascular Events With Asciminib ComparedWith Ponatinib in Previously Treated Chronic Myeloid Leukemia: A Propensity-MatchedReal-World Analysis

Layal Sharrouf

Poster Presenter: Layal Sharrouf

$Thumbnail for Reduced-Frequency Dosing of FDA-Approved Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: A Systematic Review of Maintaining Efficacy While Reducing Infection-Related Toxicity$

MM - 263

Reduced-Frequency Dosing of FDA-Approved Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: A Systematic Review of Maintaining Efficacy While Reducing Infection-Related Toxicity

Mahboob Younus Shaik

Poster Presenter: Mahboob Younus Shaik

$Thumbnail for Reducing Hospitalization During Bispecific Antibody Initiation in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Pooled Analysis of Outpatient, Step-Up, and CRS-Mitigation Strategies$

MM - 574

Reducing Hospitalization During Bispecific Antibody Initiation in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Pooled Analysis of Outpatient, Step-Up, and CRS-Mitigation Strategies

Ayse Gul Korkmaz

Poster Presenter: Ayse Gul Korkmaz